Evidence map›Paper›PMID 35288831›Full record

ArticleDigestive diseases and sciences2022

Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn's Disease.

Scott David Lee, Anand Singla, Jason Harper, Mitra Barahimi, Jeffrey Jacobs, Kendra J Kamp, Kindra Dawn Clark-Snustad

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Scott David LeeDivision of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA. ScottL@medicine.washington.edu.ORCID 0000-0001-8936-8052
Anand SinglaDivision of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA.
Jason HarperDivision of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA.
Mitra BarahimiDivision of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA.
Jeffrey JacobsDivision of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA.
Kendra J KampDivision of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA.
Kindra Dawn Clark-SnustadDivision of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA.
University of Washington · USSeattle Pacific University · US

Funding

UNIVERSITY OF WASHINGTON GI TRAINING GRANTT32DK007742 · NIDDK · UNIVERSITY OF WASHINGTON · PI GRADY, WILLIAM MALLORY · 1996 to 2022
$4.7M
NIDDK NIH HHS T32 DK007742
6 · The paper itself

Abstract

backgroundActive Crohn's disease increases the risk of strictures, fistulas, and abscesses. Less than 30% of patients with Crohn's disease achieve endoscopic remission on any therapy. Tofacitinib may be a therapeutic option for patients with refractory Crohn's disease.

aimsWe aimed to evaluate the safety and effectiveness of off-label tofacitinib for refractory Crohn's disease.

methodsWe retrospectively assessed adverse events and clinical/endoscopic response after therapy.

resultsForty-four patients were included in the safety analysis and 35 were included in the clinical and/or endoscopic assessments. The mean age was 41.8 years and the mean disease duration was 17.4 years. All patients had prior biologic exposure. Adverse events were reported in 52.3% of patients; 13.6% had ≥ 1 serious adverse event after a median 54.6 weeks of treatment. Seventy percent achieved clinical response after a mean 29.4 (SD 15.1) weeks, and 33.3% achieved clinical remission after a mean 33.4 (SD 17.6) weeks of therapy. Endoscopic improvement occurred in 25.0%, endoscopic remission in 12.5%, and endoscopic healing in 4.2% of patients after a mean 52.0 (SD 15.0) weeks of therapy. The mean Simple Endoscopic Score in Crohn's disease significantly improved from 23.1 ± 3.7 to 18.0 ± 13.7 after treatment (P = .02).

conclusionsIn the short term, tofacitinib appears well tolerated. The most common adverse event was minor infection. One serious infection and one colorectal cancer occurred. While half of patients reported adverse events, this likely reflects the severe refractory disease in this population and no new safety events were observed. Tofacitinib achieved clinical and endoscopic improvement in some patients with refractory Crohn's disease. Further research is needed to understand the long-term safety and efficacy of tofacitinib in Crohn's disease.

Indexed as

Crohn DiseaseAdultHumansPiperidinesPyrimidinesRemission InductionRetrospective StudiesPiperidinesPyrimidinestofacitinibCrohn’sDiseaseProtein kinase inhibitorRefractorySmall moleculeTofacitinib

Identifiers

PMID35288831
PMCPMC10983067
OpenAlexW4221091507

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.